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Abstract In cancer cells, loss of G1/S control is often accompanied by p53 pathway inactivation,
the latter usually rationalized as a necessity for suppressing cell cycle arrest and apoptosis.
However, we found an unanticipated effect of p53 loss in mouse and human G1-checkpoint-
deficient cells: reduction of DNA damage. We show that abrogation of the G1/S-checkpoint
allowed cells to enter S-phase under growth-restricting conditions at the expense of severe
replication stress manifesting as decelerated DNA replication, reduced origin firing and
accumulation of DNA double-strand breaks. In this system, loss of p53 allowed mitogen-
independent proliferation, not by suppressing apoptosis, but rather by restoring origin firing and
reducing DNA breakage. Loss of G1/S control also caused DNA damage and activation of p53 in an
in vivo retinoblastoma model. Moreover, in a teratoma model, loss of p53 reduced DNA breakage.
Thus, loss of p53 may promote growth of incipient cancer cells by reducing replication-stress-
induced DNA damage.
DOI: https://doi.org/10.7554/eLife.37868.001
Introduction
To prevent cells become cancerous, different cell-cycle checkpoints can be activated to halt cell
cycle progression. The G1/S checkpoint is responsible for controlling S phase entry and key effectors
of this checkpoint are the retinoblastoma (Rb) proteins pRB, p107 and p130. Anti-proliferative condi-
tions, such as lack of growth factors, suppress the activity of the D-type cyclin-dependent kinases
(CDKs) CDK4 and CDK6. This results in hypo-phosphorylation of the Rb proteins, which can then
bind E2F transcription factors thereby inhibiting the transcription of E2F target genes required for
S-phase entry (Bertoli et al., 2013; Burkhart and Sage, 2008). In a majority of human tumors, the
G1/S checkpoint is lost, for example by loss of pRB or the CDK inhibitor p16INK4A, or by overexpres-
sion of Cyclin D1 (Ho and Dowdy, 2002; Weinberg, 2007) and insensitivity to antigrowth signals is
an hallmark of tumor cells (Hanahan and Weinberg, 2000). Cells lacking the G1/S phase checkpoint
can start synthesizing DNA under non-permissive conditions which may lead to DNA damage.
To deal with DNA damage, cells have evolved another cell cycle checkpoint that is part of the
DNA-damage response (DDR) (Jackson and Bartek, 2009). Activation of the DNA damage check-
point triggers cellular senescence or cell death, thereby providing an intrinsic biological barrier
against tumor progression (Bartkova et al., 2006; Gorgoulis et al., 2005). It is often rationalized
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that inactivation of Trp53, a central player in the DDR and the most frequently mutated gene in
human cancer (Olivier et al., 2010), promotes tumorigenesis by counteracting apoptosis and senes-
cence induced by a defective G1/S checkpoint (Sherr and McCormick, 2002; Reinhardt and Schu-
macher, 2012; Polager and Ginsberg, 2009; Bunz et al., 1998; Bieging et al., 2014). However,
here we present an unanticipated effect of p53 loss in cells that lack G1/S control.
To study the consequences of G1/S checkpoint loss in a well-defined system, we used primary
mouse embryonic fibroblasts (MEFs) in which the three retinoblastoma (Rb) genes were inactivated.
Previously, we and others demonstrated that these so-called triple knockout (TKO) MEFs can enter S
phase without mitogenic signaling (Dannenberg et al., 2000; Sage et al., 2000). However, prolifera-
tion of TKO MEFs was still mitogen dependent: without mitogens, most cells became apoptotic
whereas surviving cells arrested in a G2-like state. Suppression of apoptosis by ectopic expression of
Bcl2 (TKO-Bcl2 MEFs) revealed that G2 arrest resulted from induction of p27Kip1 and p21Cip1 that
inhibit Cyclin A- and B1-dependent kinase activity (Foijer et al., 2005). Induction of p21Cip1 upon
mitogen deprivation may be indicative for DNA damage (Karimian et al., 2016). Intriguingly, we
previously showed that RNAi-mediated suppression of p53 and thereby reduction of p21Cip1 levels
revitalized CDK activity and supported mitogen-independent proliferation of Rb-protein-deficient
cells (Foijer et al., 2005). In the present study, we provide mechanistic insight into the relief of pro-
liferative arrest in mitogen-deprived TKO cells by p53 loss. We show that the DNA DSBs observed in
mouse and human cells lacking G1/S phase control are caused by replication stress reflected by
decreased replication speed and reduced origin firing. Inactivation of p53 allowed for mitogen-inde-
pendent proliferation, not only by suppressing apoptosis but also by restoring the levels of origin fir-
ing and reducing DSB formation. Similarly, in an in vivo model and in Rb-protein-deficient human
cells, DNA breakage was reduced by loss of p53.
eLife digest Healthy cells go through a strictly regulated process called the cell cycle in order to
divide. During this cycle the cell’s DNA is duplicated and the two copies are equally distributed
between the two newly formed cells. Duplicating DNA is a complex procedure that can go wrong
and damage the DNA. This damage, in turn, can cause cells to stop growing or even die.
Normal cells only start replicating their DNA when there are substances known as growth factors
in the environment. Without growth factors cells remain in the first phase of the cell cycle, known as
G1. Most cancer cells, however, lack this ‘G1 checkpoint’ and enter the cell cycle even when growth
factors are absent. This leads to DNA replication problems and damage that should cause the cells
to die. Yet a characteristic of cancer cells is that they overcome these problems to grow and divide
uncontrollably.
Cancer cells also often lack a protein called p53. Previous studies demonstrated that the lack of
p53 helps tumor cells to survive by maintaining cell growth and reducing the likelihood of cell death.
By growing cells in culture without growth factors, Benedict, van Harn et al. now show that p53 also
helps cells that lack the G1 checkpoint to continue dividing.
In the experiments, cells that lacked the G1 checkpoint but still contained the p53 protein
suffered from DNA replication problems and DNA damage, and subsequently died. Deleting p53
from these cells stimulated DNA replication, stopped cells from dying and helped to prevent the
DNA from getting damaged. Cells could thus grow and proliferate under unfavorable conditions.
Benedict, van Harn et al. also deleted p53 in tumor cells growing under the skin of mice and
observed less DNA damage in these cells than in tumor cells that still have p53.
Despite reduced levels of DNA damage, the cells still had severe DNA replication problems. It is
possible that these cells rely on mechanisms that allow just enough DNA replication to occur to
support their proliferation. Cancer cells may therefore be highly vulnerable to drugs that interfere
with these mechanisms, since they are already using them as a last resort. Future experiments will be
needed to identify these mechanisms.
DOI: https://doi.org/10.7554/eLife.37868.002
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Results
Loss of p53/p21Cip1 allows mitogen-independent proliferation of cells
lacking the G1/S checkpoint
Consistent with our previous observations (Foijer et al., 2005), mouse embryonic fibroblast (MEFs)
lacking the three retinoblastoma proteins and overexpressing the anti-apoptotic gene Bcl2 (TKO-
Bcl2 MEFs) ceased proliferation upon mitogen deprivation (Figure 1A, black line) and arrested in a
G2-like state (Figure 1C, upper panel). We also reported that proliferation was rescued by RNAi-
mediated knockdown of Trp53, the gene that encodes the p53 protein (TKO-p53RNAi MEFs)
(Foijer et al., 2005). However, in recent experiments, proliferation of mitogen-starved TKO-
p53RNAi MEFs appeared transient and was followed by severe cell loss (Figure 1A, green line), pos-
sibly as a result of residual p53 activity (Figure 1—figure supplement 1A). We therefore exploited
CRISPR/Cas9 technology to create full Trp53 knockout (KO) TKO MEFs (Figure 1—figure supple-
ment 1A). Disruption of p53 clearly rescued proliferation of mitogen-starved TKO MEFs (TKO-
p53KO) and this effect was even greater in TKO MEFs expressing Bcl2 (TKO-Bcl2-p53KO), which
reached 100% confluency (Figure 1A, blue and red lines). The improved proliferative capacity was
accompanied by reduced apoptosis (Figure 1B) and the absence of G2 arrest (Figure 1C, lower
panel, Figure 1—figure supplement 1B). Mitogen-deprived TKO-Bcl2-p53KO cells maintained a
cell cycle profile similar to cells cultured in the presence of mitogens (Figure 1C, lower panel) and,
unlike TKO-Bcl2 cells, continued to incorporate high levels of nucleotides (Figure 1D).
Not only loss of p53, but also disruption of its downstream target Cdkn1a, the gene that encodes
the p21Cip1 protein (Figure 1—figure supplement 1C), rescued proliferation of mitogen-deprived
TKO-Bcl2 cells (Figure 1E). Apparently, the induction of p21Cip1, which we previously found to
inhibit Cyclin A- and B1-dependent kinases (Foijer et al., 2005), was critical for G2-like arrest of
mitogen-deprived TKO cells. The p53/p21Cip1 axis is part of the DNA damage response (DDR) and
its activation is consistent with the high levels of DNA double-strand breaks (DSBs) that accumulated
in arrested TKO-Bcl2 cells (van Harn et al., 2010). To understand how disruption of p53/p21Cip1 res-
cued proliferation, we investigated the mechanism of DSB formation.
Mitogen deprivation causes S-phase delay
We studied cell cycle progression of individual cells using the Fucci system, in which fluorescent pro-
teins fused to the degradation motifs of Cdt1 and Geminin mark G1 and S/G2 cells, respectively
(Sakaue-Sawano et al., 2008). In the presence of mitogens, TKO-Bcl2 and TKO-Bcl2-p53KO MEFs
proliferated with a cell-cycle duration of 10 to 15 hr (Figure 2A,B, left). In the absence of mitogens,
TKO-Bcl2 MEFs arrested in S/G2 phase, either immediately or after one cell cycle (Figure 2A, right).
In contrast, mitogen-deprived TKO-Bcl2-p53KO MEFs could be followed for two or three cell divi-
sions (Figure 2B, right), although G1 and S/G2 phase durations were increased, together encom-
passing 15 to 30 hr. These tracking experiments confirm that TKO-Bcl2-p53KO MEFs can proliferate
in the absence of mitogens albeit at slower pace.
p53/p21Cip1 knockout suppresses DSBs formation
Cell cycle delay may be caused by DSBs that accumulate in mitogen-deprived TKO-Bcl2 MEFs
(van Harn et al., 2010). This level was comparable to irradiation with 20 Gy, which is expected to
severely impair mitosis resulting in cell death (Zachos et al., 2003). Nonetheless, TKO-Bcl2-p53KO
and TKO-Bcl2-p21KO MEFs were able to proliferate mitogen-independently. We therefore investi-
gated whether Trp53 or Cdkn1a inactivation affected DSB formation as a consequence of mitogen
deprivation by performing neutral comet assays (Olive and Bana´th, 2006). Mitogen restriction of
TKO-Bcl2 MEFs caused a clear increase in tail moment, an indicator of the level of DSBs (Figure 3A,
B). In contrast, the tail moments in TKO-Bcl2-p53KO and TKO-Bcl2-p21KO MEFs were not signifi-
cantly increased by mitogen depletion (Figure 3B) although the basal levels of DSBs (i.e., in the
presence of mitogens) were somewhat higher compared to TKO-Bcl2 cells. Possibly, MEFs accumu-
lated some DNA damage under optimal culture conditions that was tolerated or not adequately
repaired in the absence of p53/p21Cip1 activity (Levine and Oren, 2009; Williams and Schumacher,
2016). Nevertheless, the critical observation here is that the induction of DNA breakage due to
mitogen deprivation was suppressed in the absence of p53/p21Cip1.
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Figure 1. Loss of p53/p21Cip1 promotes proliferation of mitogen-deprived MEFs lacking G1/S phase checkpoint. (A) IncuCyte growth curves of TKO-
Bcl2 (black), TKO-p53RNAi (green), TKO-p53KO (blue) and TKO-Bcl2-p53KO (red) MEFs in the absence of 10% FCS. (B) Apoptosis levels of TKO-Bcl2
(black), TKO-p53RNAi (green), TKO-p53KO (blue) and TKO-Bcl2-p53KO (red) MEFs in the absence of 10% FCS. Apoptosis was measured by fluorescent
signal upon caspase three cleavage and normalized to cell confluency. (C) Cell cycle distribution based on propidium iodide content of TKO-Bcl2 MEFs
Figure 1 continued on next page
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It is known that p53 modulates different DNA repair pathways (Bieging et al., 2014;
Williams and Schumacher, 2016). Could the level of DSBs in mitogen-deprived p53KO MEFs be
reduced by passage through M phase and subsequent repair in G1? To examine this possibility, we
blocked cell cycle progression towards G1 by culturing cells in medium without mitogens, but con-
taining nocodazole (Figure 3—figure supplement 1). This allowed us to measure the level of DSBs
in TKO-Bcl2 and TKO-Bcl2-p53KO cells in comparable cell cycle phases, between S and M phase. In
the presence of nocodazole, the same results were obtained: mitogen-deprived TKO-Bcl2 MEFs
showed the expected increase in tail moment, while the tail moments of TKO-Bcl2-p53KO MEFs
were still not increased (Figure 3C).
To directly investigate whether p53 status affected repair of replication-stress-induced DSBs, we
treated mitogen-stimulated TKO-Bcl2 MEFs with 2 mM hydroxyurea (HU) for 1 hr in order to induce
and alleviate replication stress instantaneously. HU depletes the cells of nucleotides, which results in
stalling and collapsing of replication forks and hence DNA breakage (Bianchi et al., 1986;
Koc¸ et al., 2004). When comparing cells harvested immediately after HU treatment and cells har-
vested 30 min after HU treatment, we observed an equally strong decrease in tail moment in TKO-
Bcl2 and in TKO-Bcl2-p53KO MEFs (Figure 3D). This indicates that the repair of DSBs induced by
HU treatment was independent of p53 status. Assuming that repair of replication-stress-induced
DSBs under mitogen-deprived conditions follows similar rules, these results suggest that reduced
levels of DSBs in mitogen-deprived TKO-Bcl2-p53KO cells resulted from suppressed formation
rather than increased repair of DSBs.
Mitogen-deprived TKO-Bcl2 MEFs suffer from replication stress
To study the mechanism of DNA breakage, we assessed the quality of DNA replication in mitogen-
deprived TKO-Bcl2 MEFs by looking at co-localization of the thymidine analogue chloro-deoxyuri-
dine (CldU, marking DNA replication) and g-H2AX (marking DNA damage). While the number of
cells containing CldU foci gradually decreased in mitogen-starved TKO-Bcl2 MEFs, virtually all CldU
foci that were still present after 4 and 7 days co-localized with g-H2AX foci (Figure 4A,B). Further-
more, the gradual increase of phosphorylated Chk1 (pChk1), a target of ataxia telangiectasia related
(ATR), is indicative for accumulation of single-stranded DNA (Figure 4C). Taken together, these
results are indicative for perturbed replication in mitogen-deprived TKO-Bcl2 MEFs.
We next visualized the progression of individual replication forks using a DNA fiber assay
(Tuduri et al., 2010). Sequential pulse-labeling of newly synthesized DNA strands with the thymidine
analogs CldU (red tracks) and iodo-deoxyuridine (IdU, green tracks) identifies ongoing replication
forks and new origin firing (Figure 5A). The length of double-labelled tracks in TKO-Bcl2 MEFs cul-
tured with FCS indicated an average fork speed of 1.66 kb/min (Figure 5B). In the absence of p53
the average fork speed was somewhat lower, 1.37 kb/min, consistent with a previous study
(Klusmann et al., 2016). Mitogen deprivation caused a progressive decline in replication speed,
somewhat unexpectedly not only in arresting TKO-Bcl2 MEFs but also in proliferating TKO-Bcl2-
p53KO MEFs (Figure 5B). Prolonged S-phase and decelerated DNA synthesis indicate that mitogen-
deprived TKO-Bcl2-p53KO MEFs were able to proliferate despite sustained replication stress.
Nucleotide deficiency contributes to perturbed DNA replication
Disruption of the nucleotide pool can contribute to replication stress (Bester et al., 2011;
Poli et al., 2012) and may therefore be the underlying cause of reduced replication speed, DSB
Figure 1 continued
(upper panel) and TKO-Bcl2-p53KO MEFs (lower panel) in the absence of 10% FCS for the indicated days. (D) BrdU flow cytometry analysis of the cell
cycle distribution of TKO-Bcl2 and TKO-Bcl2-p53KO MEFs in the absence of 10% FCS for the indicated days. Percentage of BrdU-labeled cells is
indicated. (E) IncuCyte growth curves of TKO-Bcl2 (black), TKO-Bcl2-p53KO (red) and TKO-Bcl2-p21KO (blue) MEFs in the absence of 10% FCS.
Experiments in A, B and E were performed in triplicate. Error bars show standard deviation (sd).
DOI: https://doi.org/10.7554/eLife.37868.003
The following figure supplement is available for figure 1:
Figure supplement 1. Reduced G2 arrest in mitogen-starved TKO-p53RNAi and TKO-p53KO MEFs.
DOI: https://doi.org/10.7554/eLife.37868.004
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Figure 2. Loss of p53 rescues G2 arrest in mitogen-deprived TKO-Bcl2 MEFs. Timing of cell cycle phases in (A) TKO-Bcl2 MEFs and (B) TKO-Bcl2-
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DOI: https://doi.org/10.7554/eLife.37868.005
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formation and G2-like arrest in mitogen-deprived TKO-Bcl2 MEFs. Mitogen deprivation is a strong
anti-proliferative signal that may inhibit MYC transcription factors and therefore repress genes
involved in nucleotide synthesis (Gassmann et al., 1999; Perna et al., 2012). Indeed, we found that
mitogen-deprivation of TKO-Bcl2 cells reduced transcript levels of phosphoribosyl pyrophosphate
amidotransferase (Ppat) and inosine monophosphate dehydrogenase 1 and 2 (Impdh1 and Impdh2),
genes involved in purine metabolism, 2-fold (Figure 5—figure supplement 1A). Reduced levels of
nucleotide synthesis enzymes could impair DNA replication by disturbing the balance in the dNTP
pool. Indeed, RNAi-mediated suppression of Ppat expression (Figure 5—figure supplement 1B)
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Figure 3. Loss of p53 reduces DNA double-stranded breaks. (A) Representative comets of nuclei of TKO-Bcl2, TKO-Bcl2-p53KO MEFs and TKO-Bcl2-
p21KO MEFs stained with propidium iodide in the presence or absence of 10% FCS (7 days). (B) Tail moments obtained from TKO-Bcl2, TKO-Bcl2-
p53KO and TKO-Bcl2-p21KO MEFs cultured in the presence or absence of 10% FCS (7 days). (C) Tail moments obtained from TKO-Bcl2 and TKO-Bcl2-
p53KO MEFs cultured in the presence or absence of 10% FCS (2 days) and in the presence of nocodazole. (D) Tail moments obtained from TKO-Bcl2
and TKO-Bcl2-p53KO MEFs immediately and 30 min after 1 hr treatment with 2 mM HU. In B, C and D, box plots represent interquartile ranges,
horizontal bars denote the median and points indicate outliers. For each condition, more than 50 cells were analyzed using the CASP software.
Significance is indicated (1-way Anova nonparametric Kruskal-Wallis test).
DOI: https://doi.org/10.7554/eLife.37868.006
The following figure supplement is available for figure 3:
Figure supplement 1. Nocodazole-induced cell cycle arrest to prevent G1 entry.
DOI: https://doi.org/10.7554/eLife.37868.007
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reduced the replication speed in mitogen-stimulated TKO-Bcl2 MEFs from 1.25 kb/min to 0.84
(shRNA #1) and 0.86 (shRNA #2) kb/min (Figure 5—figure supplement 1C).
Conversely, replication speed in mitogen-deprived TKO-Bcl2 MEFs could be partially rescued by
the exogenous supply of nucleosides. Similar to previous experiments, one day of mitogen depriva-
tion decreased the average fork speed by ±30%, in this experiment from 0.94 kb/min to 0.65 kb/
min. In contrast, when cells were supplemented with nucleosides, reduction of replication speed was
less pronounced (from 1.03 kb/min to 0.83 kb/min) (Figure 5—figure supplement 1D). However,
daily nucleosides supplementation did not alleviate the proliferation defect of mitogen-deprived
TKO-Bcl2 MEFs: G2 accumulation was hardly affected (Figure 5—figure supplement 1E) and also
Chk1 phosphorylation and p21Cip1 induction were not reduced (Figure 5—figure supplement 1F).
As we observed that mitogen-independent proliferation upon p53 loss did not require restoration of
replication speed (Figure 5B), this indicates that rather than decelerated DNA replication another
factor was causal to G2 arrest upon mitogen deprivation.
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The following figure supplements are available for figure 5:
Figure supplement 1. Nucleotide deficiency is not causal to G2 arrest.
DOI: https://doi.org/10.7554/eLife.37868.010
Figure supplement 2. DNA replication stress induced by 0.3 and 2 mM Hydroxyurea.
DOI: https://doi.org/10.7554/eLife.37868.011
Benedict et al. eLife 2018;7:e37868. DOI: https://doi.org/10.7554/eLife.37868 9 of 25
Research article Cancer Biology
Reduced DNA breakage by p53 knockout is associated with increased
origin firing
Previously, we showed that inhibition of CDK activity by p27Kip1 and p21Cip1 was critical for arrest of
mitogen-deprived TKO-Bcl2 MEFs (Foijer et al., 2005). Since CDK activity is required to activate ori-
gins of replication (Fragkos et al., 2015; Me´ndez and Stillman, 2003), origin firing may be per-
turbed in mitogen-deprived TKO-Bcl2 MEFs. Indeed, among CldU/IdU-labelled DNA fibers from
mitogen-deprived TKO-Bcl2 MEFs, staining patterns indicative for new origin firing were significantly
reduced (Figure 5C). In contrast, in TKO-Bcl2-p53KO MEFs, origin firing was not disturbed during
the first days of mitogen deprivation and maintained levels similar as in mitogen-stimulated cells
(Figure 5C). Only after 5 days of mitogen deprivation, origin firing was reduced, which may be
related to the state of confluency that was reached by that time (Figure 1A). Similar to TKO-Bcl2-
p53KO MEFs, also TKO-Bcl2-p21KO MEFs maintained normal origin firing during the first days of
mitogen deprivation (Figure 5C).
The increased level of origin firing upon loss of p53/p21Cip1 contrasts to a recent publication by
Roy et al. who identified a transcription-independent function of p53 in balancing replication fork
homeostasis and, in contrast to our findings, observed a decrease in the level of origin firing upon
loss of p53 (Beroukhim et al., 2010). An explanation for this seeming discrepancy may be found in
comparing the different replication stress conditions. Roy et al. studied the role of p53 in conditions
with a low dose of HU that did not induce DSBs. In contrast, by serum starvation we induced severe
replication stress as observed by the drastic decrease of replication fork progression and induction
of DNA breaks (Figure 5B). We therefore compared the consequences of low versus high doses of
HU. A low dose of HU (300 mM) did not induce DNA DSBs whereas a high dose of HU (2 mM) did
(Figure 5—figure supplement 2A). Consistent with Roy et al., loss of p53 reduced the level of origin
firing upon treatment with 300 mM HU. However, loss of p53 did not change the level of origin firing
after treatment with the high dose of HU (2 mM) (Figure 5—figure supplement 2B).
Collectively, our results suggest that under conditions of severe replication stress, restoration of
the level of origin firing upon p53 loss prevents DNA breakage, allowing mitogen-independent pro-
liferation of TKO-Bcl2-p53KO MEFs.
Also in human cells inactivation of p53 is associated with reduced DNA
DSBs
To investigate whether p53 affects DNA breakage under replication stress conditions in human cells,
we used the human retinal pigment epithelial cell line RPE-1. The G1/S phase checkpoint was per-
turbed either by inactivating all three retinoblastoma genes, RB, RBL1 and RBL2 (TKO; Figure 6A)
or by overexpressing a non-degradable form of human Cyclin D1 (CyclinD1; Figure 6B). Overexpres-
sion of Cyclin D1 is biologically relevant since the gene encoding Cyclin D1 represents the second
most frequently amplified locus in the human cancer genome (Beroukhim et al., 2010). In addition,
in many human tumors overexpression of D type cyclins takes place in the absence of detectable
genomic alterations (Hosokawa and Arnold, 1998). In the presence of mitogens, TKO and CyclinD1
RPE-1 cells proliferated faster than wild type RPE-1s (Figure 6—figure supplement 1A). 24 hr after
mitogen-deprivation, wild type RPE-1s arrested in the G1 phase of the cell cycle (Figure 6C),
whereas both, TKO and CyclinD1 cultures maintained a normal cell cycle profile up to 72 hr
(Figure 6D and E, respectively). Upon prolonged mitogen starvation for more than 4 days, TKO and
CyclinD1 cells started to die (Figure 6—figure supplement 1B). Cell death could not be avoided by
overexpression of Bcl2 (Figure 6—figure supplement 1C, D and E) nor by additional inactivation of
TP53 (Figure 6F,G and Figure 6—figure supplement 1F). Apparently, RPE-1 cells lacking the G1/S
phase checkpoint were very sensitive to apoptosis in the absence of mitogenic stimulation, which
could not easily be suppressed. Nonetheless, we could follow the behavior of these cells during the
first days of mitogen deprivation. Similar to TKO-Bcl2 MEFs, p53-proficient TKO-Bcl2 RPE-1s showed
induction of DNA DSBs after one day of mitogen starvation. In contrast, no DSB induction was seen
in TKO-Bcl2-p53KO RPE-1s (Figure 6H). Similarly, mitogen starvation hardly induced DSBs in
CyclinD1-Bcl2-p53KO RPE-1s compared to CyclinD1-Bcl2 RPE-1s (Figure 6I). Mitogen-deprived
TKO-Bcl2 and CyclinD1-Bcl2 RPE-1s showed a decrease in the level origin firing (Figure 6J,K). In
contrast, TKO-Bcl2-p53KO and CyclinD1-Bcl2-p53KO RPE1-s maintained normal levels of origin
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Figure 6. Loss of p53 reduces DNA double-strand breaks in human cells. (A) Rb, Rbl1 and Rbl2 protein levels in wt and TKO RPE-1s. Anti-actin was
used as a loading control. (B) Cyclin D1 protein levels in wt and CyclinD1 RPE-1s. Anti-actin was used as a loading control. (C, D, E) Cell cycle
distribution based on propidium iodide content of wt (C), TKO (D) and CyclinD1 (E) RPE-1s in the absence of 10% FCS for the indicated hours. (F) p53
and p21Cip1 protein levels in wt, Bcl2-p53KO and TKO-Bcl2-p53KO RPE-1s. Anti-actin was used as a loading control. (G) p53 and p21Cip1 protein levels
Figure 6 continued on next page
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firing after mitogen deprivation (Figure 6J,K), although there is no difference in replication fork
speed upon mitogen-deprivation (Figure 6—figure supplement 1G and F).
These results show that also in human cells inactivation of p53 in G1/S phase checkpoint defective
cells reduced the accumulation of DNA DSBs following mitogen deprivation, possible by rescuing
the level of origin firing.
The role of p53 loss in tumor development
To investigate whether the accumulation of DNA DSBs also operates in vivo to impede tumor
growth, we studied retinoblastoma development in chimeric mice generated by blastocyst injection
of Rb-/-Rbl2-/-embryonic stem cells (ESCs) (Dannenberg et al., 2000). Remarkably, murine retino-
blastomas showed pronounced p53 and g-H2AX staining (Figure 7A). However, by sequencing, p53
appeared wild-type in a separate series of seven tumors, indicating that in this model retinoblasto-
mas did activate the DDR but could still colonize the entire eyeball. To study if p53 inactivation
accelerates tumorigenesis, we inactivated p53 in Rb-/- Rbl2-/- ESCs using CRISPR/Cas9-mediated
gene disruption. However, no chimeric animals were obtained from Rb-/-Rbl2-/-p53-/- ESCs, likely
indicating that combined ablation of the Rb and p53 pathways is incompatible with embryonic
development.
As an alternative in vivo readout, we injected Rb-/-Rbl2-/- and Rb-/-Rbl2-/-p53-/- mouse ESCs under
the skin of nude mice. Rb-/-Rbl2-/- ESCs developed a teratoma in 4 out of 6 mice; in contrast,
Rb-/-Rbl2-/-p53-/- ESCs developed a tumor in 6 out of 6 injected mice. On average the
Rb-/-Rbl2-/-p53-/- tumors were larger than Rb-/-Rbl2-/- tumors (Figure 7B), although there is a 11%
chance that the difference is accidental (p=0.1116, unpaired t-test). Teratomas of both genotypes
mainly showed early neuronal differentiation and stained positive for the replication stress marker g-
H2AX (Figure 7C), suggesting that all tumors were suffering from replication stress. To assess the
presence of DSBs, we performed a neutral comet assay on teratoma tissues. Three of the four
Rb-/-Rbl2-/- teratomas showed an increase in tail moment compared to the tail moments of
Rb-/-Rbl2-/-p53-/- teratomas (Figure 7D). Of note, unlike the other tumors, the largest Rb-/-Rbl2-/-
tumor (marked with asterisk in Figure 7B,D) had high levels of infiltrating neutrophils, which possibly
explains its bigger size as well as the low level of DNA DSBs.
Although the number of tumors was small, p53 knockout teratomas showed a trend towards
lower levels of DSBs and accelerated tumor growth. Therefore, both our in vitro as well as in vivo
data suggest that inactivation of p53 in G1/S checkpoint deficient cells contributes to tumorigenesis
by reducing DNA DSBs (Figure 7E).
Discussion
We have previously shown that apoptosis-resistant MEFs that lack the G1/S phase checkpoint (TKO-
Bcl2 MEFs) can undergo unscheduled S-phase entry. Here we show that they do so at the expense
of severe replication stress and the accumulation of DNA DSBs, which ultimately causes G2-like cell
cycle arrest. Inactivation of p53 allowed mitogen-independent proliferation, which remarkably was
not only associated with alleviated G2 arrest but also with reduced DNA breakage and restored ori-
gin firing. The firing of origins requires Cyclin-CDK activity (Fragkos et al., 2015; Me´ndez and
Figure 6 continued
in wt, CyclinD1-Bcl2 and CyclinD1-Bcl2-p53KO RPE-1s. Anti-actin was used as a loading control. (H, I) Tail moments obtained from TKO-Bcl2, TKO-Bcl2-
p53KO (H) and CyclinD1-Bcl2 and CyclinD1-Bcl2-p53KO (I) RPE1-s cultured in the presence or absence of 10% FCS (1 day). Box plots represent
interquartile ranges, horizontal bars denote the median and points are outliers. For each condition, more than 50 cells were analyzed using the CASP
software. Significance is indicated (1-way Anova nonparametric Kruskal-Wallis test). (J, K) Quantification of origin firing in TKO-Bcl2, TKO-Bcl2-p53KO (J)
and CyclinD1-Bcl2 and CyclinD1-Bcl2-p53KO (K) RPE1-s cultured in the presence or absence of 10% FCS for 1 day. 1st label and 2nd label origins are
shown as percentage of all labelled tracks (from two independent experiments). Significant differences between average values are indicated (Student’s
t-test).
DOI: https://doi.org/10.7554/eLife.37868.012
The following figure supplement is available for figure 6:
Figure supplement 1. Response of RPE1 cells to mitogen starvation
DOI: https://doi.org/10.7554/eLife.37868.013
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Figure 7. p53 inactivation promotes tumor growth in vivo. (A) Examples of HE and immunohistochemical stainings for g-H2AX and p53 of two
retinoblastomas from Rb-/-Rbl2-/- chimeric mice. (B) Tumor weight of Rb-/-Rbl2-/- (black) and Rb-/-Rbl2-/-p53-/- (red) teratomas 20 days after injection of
ESCs in nude mice. Black dot marked with an asterisk (*) indicates the only tumor with high levels of infiltrating neutrophils. (C) Tail moments of
Rb-/-Rbl2-/- (black) and Rb-/-Rbl2-/-p53-/- (red) teratomas plotted against the tumor weight. Spearman’s correlation coefficient between tail moment and
Figure 7 continued on next page
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Stillman, 2003). In mitogen-deprived TKO-Bcl2 MEFs, CDK activity was low due to the high levels of
p21Cip1 and p27Kip1 explaining the low level of origin firing. It is therefore likely that upon p53 inacti-
vation and therefore reduction of p21Cip1, CDK activity increased (Foijer et al., 2005) and hence
promoted origin firing. Consistently, we found that also genetic inactivation of p21Cip1 restored ori-
gin firing and promoted proliferation of mitogen-deprived TKO-Bcl2 MEFs. Importantly, this phe-
nomenon was not restricted to murine cells, but also observed in human RPE-1 cells: mitogen
deprivation restricted origin firing and induced DNA breakage in G1/S-checkpoint-defective RPE-1s,
and both could be reverted by inactivation of p53. However, for as yet unknown reasons, RPE-1 cells
appeared highly sensitive to apoptosis and therefore the damage-reducing effect of p53 loss did
not translate into mitogen-independent proliferation.
While restored origin firing upon ablation of the p53/p21Cip1 axis is mechanistically plausible, we
have not directly proven that DNA breakage as a consequence of replication stress was prevented
by increased origin firing. Related to this, an important question is whether p53 inactivation reduced
the formation of DNA breaks or stimulated DSB repair. Apart from its role as transcription factor,
p53 has many transcription-independent functions, among which inhibition of DNA DSB repair by
both non-homologous end joining (NHEJ) and homologous recombination (HR) (Menon and Povirk,
2014; Sengupta and Harris, 2005; Akyu¨z et al., 2002; Dudenho¨ffer et al., 1998). However, we
show that KO of the p53 transcription target p21Cip1 phenocopied the effects of KO of p53 in TKO-
Bcl2 MEFs, arguing against a transcription-independent role of p53 in suppressing DNA repair. Fur-
thermore, increased DNA repair by NHEJ in G1 phase is unlikely as the levels of DSBs in serum-
starved TKO-Bcl2-p53KO MEFs remained low when G1 entry was prevented by artificially arresting
cells in M-phase. In this experiment it remains possible that an increase in HR activity during S/G2
phase contributed to less DNA breaks in mitogen-deprived p53KO MEFs. Also this possibility seems
unlikely as the repair of HU-induced DSBs was not affected by p53 status. However, this experiment
does not exclude the possibility that under mitogen-deprived conditions p53 suppressed DSB repair.
With this restriction, we hypothesize that abrogation of p53 reduced the formation of DNA breaks,
rather than facilitated repair.
Novel roles of pRB and p53 are emerging but it is unclear to which extent they are implicated in
suppression of cancer. Apart from its well documented role in cell cycle control, pRB has emerged
as a multi-functional protein involved in a wide range of biological processes including chromatin
architecture, cohesion, chromosome condensation during mitosis, DNA replication via interaction
with replication components and involvement in DNA repair processes such as HR and NHEJ (Ve´lez-
Cruz and Johnson, 2017; Dick and Rubin, 2013; Huang et al., 2015). We suggest that these other
functions of pRB do not play a role in the accumulation of DNA damage in Rb-deficient cells since
we observed the same phenotype in Rb-proficient Cyclin D1 overexpressing RPE-1s. Thus, the accu-
mulation of DNA DSBs in mitogen-deprived conditions can be attributed to loss of the G1/S phase
checkpoint and not to other functions of the pRB protein or its family members.
It has been described that some ribosomal proteins have a function in the DNA damage response
that is activated upon intrinsic replication stress and mediated through the Mdm2-p53 axis
(Xu et al., 2016). In addition, some ribosomal proteins act as a sensor for DNA damage and directly
participate in the process of DNA repair. In this study, we cannot exclude an effect of p53 loss on
the extra-ribosomal functions of these proteins. Also p53 has functions outside its canonical role in
the DDR. Recently, a novel transcription-independent role for p53 in balancing replication homeosta-
sis was reported. The p53 protein can bind to replication forks and facilitate replication fork restart
Figure 7 continued
tumor weight is  0.78. Black dot marked with an asterisk (*) indicates the only tumor with high levels of infiltrating neutrophils. One Rb-/-Rbl2-/-p53-/-
(red) teratoma could not be analyzed for DNA DSBs due to the small tissue size. For each teratoma, more than 50 cells were analyzed using the CASP
software. (D) Examples of HE and immunohistochemical staining for g-H2AX of Rb-/-Rbl2-/- and Rb-/-Rbl2-/-p53-/- teratomas. Scale bar is 50 mm. (E)
Schematic model for how p53 inactivation reduces DNA DSBs in mitogen-deprived cells lacking the G1/S checkpoint. Cells that lost the G1/S phase
checkpoint suffer from replication stress leading to DNA DSBs. Activation of p53 and p21Cip1 inhibits CDK activity and thereby inhibits the firing of new
origins leading to more DNA damage and establishment of the G2-like arrest (left panel). Inactivation of p53 and therefore its downstream protein
p21Cip1 increases CDK activity and allows origins to fire. Restored levels of origin firing rescues stalled forks, causing less DNA DSB formation and
enabling proliferation (right panel).
DOI: https://doi.org/10.7554/eLife.37868.014
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in replication stress conditions (Roy et al., 2018). Since we found a transcription-dependent role of
p53 in suppressing origin firing, we hypothesize that the two different effects of p53 loss reflect dif-
ferent functions of p53 that operate side by side: dependent on the severity of replication stress,
p53 facilitates replication fork restart and suppresses the firing of new origins.
Others have shown that disruption of the nucleotide pool can contribute to replication stress,
DNA breakage and cell death in oncogene-expressing cells (Bester et al., 2011; Poli et al., 2012;
Beck et al., 2012; Pfister et al., 2015). We were able to partially rescue replication speed in mito-
gen-deprived TKO-Bcl2 MEFs by exogenous supply of nucleosides. However, increased replication
speed was not sufficient to overcome G2 arrest and to support normal cell cycle progression. Fur-
thermore, we found that despite the capacity of TKO-Bcl2-p53KO MEFs to proliferate mitogen-inde-
pendently, replication speed was still reduced. These observations indicate that another factor
rather than the speed of DNA synthesis was critical for DNA breakage and G2 arrest in mitogen-
deprived TKO-Bcl2 cells. As only origin firing but not replication speed was affected by p53 status,
we favor a scenario where restoration of origin firing upon inactivation of p53, given the involvement
of p21Cip1 likely as a result of restored CDK activity, suppressed DNA breakage and allowed mito-
gen-independent proliferation.
Loss of the Rb and p53 pathways frequently occur and co-occur in human tumors (Polager and
Ginsberg, 2009). The p53 gene is mutated in more than 50% of human cancer, and mutations in
other genes that affect p53 function occur in many, if not all, tumors that retain a normal p53 gene
(Perri et al., 2016). In addition, most human tumors lack the G1/S phase checkpoint.
For example many human tumors overexpress D-type cyclins and CCND1 represents the second
most frequently amplified locus in the human cancer genome (Hosokawa and Arnold, 1998;
Menon and Povirk, 2014). Furthermore, evading apoptosis is one of the hallmarks of cancer and
the anti-apoptotic gene Bcl2, which is used in this study to suppress apoptosis, is commonly overex-
pressed in many types of cancer, including renal, prostate, gastric, lung and colorectal cancer, neuro-
blastoma, non-Hodgkin’s lymphoma and acute and chronic leukemia (Frenzel et al., 2009;
Kirkin et al., 2004). Thus, most tumor cells harbor the type of mutations used in this study. Whereas
we can only speculate about the precise number of cancer types that harbor the exact combination
of Rb, p53 and Bcl2 aberrations as used in this study, there are examples known. For example,
approximately 90% of small cell lung cancer tumors have lost both p53 and Rb (Sekido et al., 2003).
Beside this, small cell lung tumors are also characterized by expression of Bcl2 (Kaiser et al., 1996).
Furthermore, human retinoblastoma originates from an intrinsic death-resistant precursor cell
(Xu et al., 2009), is characterized by mutations in the Rb gene and it is suggested that the p53 path-
way is inactivated (Xu et al., 2009; Laurie et al., 2006). Although p53 mutations are infrequent in
human retinoblastomas, the p53 pathway may be intrinsically attenuated upon RB1 loss by miR-24-
mediated downregulation of p14ARF (To et al., 2012) and by NANOS-mediated suppression of p53-
activating kinases (Miles et al., 2014). Other studies suggested that RB1-deficient retinal cells
achieve attenuation of the p53 pathway by high expression of MDM2 and MDMX (Xu et al., 2009;
Laurie et al., 2006), although a recent paper revealed critical p53-independent functions of high
MDM2 expression (Qi and Cobrinik, 2017).
In our chimeric mouse model of retinoblastoma, we found evidence for DNA damage, but loss of
p53 was not a requirement for development of eye-filling tumors. Unfortunately, we could not study
the effect of p53 loss, but using a hereditary retinoblastoma model, others reported a dramatic
effect of p53 inactivation. When Rb was conditionally inactivated in retinal progenitor cells in a
p107-/- background, non-invasive retinoblastomas developed with a penetrance of 60%. Upon addi-
tional inactivation of p53, aggressive, invasive bilateral retinoblastomas developed with 100% pene-
trance and reduced latency (Dyer et al., 2005; Zhang et al., 2004). Importantly, evidence has been
obtained that murine retinoblastomas originate from an intrinsically death-resistant cell of origin
(Chen et al., 2004). We therefore propose that the tumor promoting effect of attenuated p53 activ-
ity was not due to abrogation of an apoptotic response but rather required for maintaining sufficient
CDK activity to counteract the deleterious effects of replication stress. We obtained support for such
tumor-promoting effect of p53 ablation in an Rb-/-Rbl2-/- teratoma model: tumor size was inversely
correlated with the level of DNA breaks and Rb-/-Rbl2-/-p53-/- teratomas generally showed lower lev-
els of DNA breaks than Rb-/-Rbl2-/- teratomas.
Finally, our results are likely related to intriguing observations that at least for some tumor types
the outgrowth of early cancerous lesions is prohibited by activation of the DDR (Bartkova et al.,
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2006). It has been suggested that oncogene activation can directly cause replication stress by
hyper-stimulating DNA replication, which activates the ATR-Chk1 axis (Hills and Diffley, 2014;
Di Micco et al., 2006; Halazonetis et al., 2008). Furthermore, frequent DNA breakage associated
with replication stress activates the complementary ATM-Chk2-p53 module that provides a strong
barrier to proliferation by inducing apoptosis or permanent cell cycle arrest. It has therefore been
suggested that activation of the DDR may explain the strong selective pressure for loss of p53 in
human cancer (Halazonetis et al., 2008). Rather than a direct consequence of oncogene activation,
replication stress in our system was the consequence of the combination of Rb-protein deficiency
(hyper-activating E2F transcription factors) and growth-restricting conditions (the absence of mito-
genic signaling), leading to DNA breakage and activation of the DDR. Furthermore, we found loss of
p53 not only abrogated cell cycle arrest and apoptosis, but also suppressed the induction of DNA
damage itself, providing a novel mechanistic explanation for the frequent co-occurrence of p53 and
pRb pathway inactivation in cancer.
Materials and methods
Key resources table
Reagent type
(species) or
resource Designation
Source or
reference Identifiers Additional information
Cell line
(mus musculus)
male
TKO-Bcl2
mouse embryonic
fibroblasts (MEFs)
PMID:16338659
Cell line
(mus musculus)
male
TKO-Bcl2-p53KO MEFs This paper N/A Knockout of p53 in
TKO-Bcl2 MEFs,
described in the
materials and methods
Cell line
(mus musculus)
male
TKO-p53RNAi MEFs PMID:16338659
Cell line
(mus musculus)
male
TKO-p53KO MEFs This paper N/A Knockout of p53 in
TKO MEFs, described in the
materials and methods
cell line
(mus musculus)
male
Rb-/-Rbl2-/- mESCs PMID: 15574596
Cell line
(mus musculus)
male
Rb-/-Rbl2-/-p53-/- mESCs This paper Knockout of p53
in Rb-/-Rbl2-/-, described
in the
materials and methods
Cell line
(homo sapiens)
female
RPE-1 hTERT ATCC Cat# CRL-4000 RRID:CVCL_4388
Cell line
(homo sapiens)
female
TKO RPE-1s This paper N/A Knockout of Rb,
Rbl1 and Rbl2 in
RPE-1-hTERT cells,
described in material
and methods
Cell line
(homo sapiens)
female
TKO-Bcl2 RPE-1s This paper N/A Knockout of Rb,
Rbl1, Rbl2 and
overexpression of
Bcl2 in RPE-1-hTERT
cells, described in
material and methods
Cell line
(homo sapiens)
female
TKO-Bcl2-p53KO RPE-1s This paper N/A Knockout of Rb, Rbl1,
Rbl2 and TP53 and
overexpression of Bcl2 in
RPE-1-hTERT cells,
described in material and
methods
Continued on next page
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Continued
Reagent type
(species) or
resource Designation
Source or
reference Identifiers Additional information
Cell line
(homo sapiens)
female
CyclinD1 RPE-1s This paper N/A Overexpression of
non-degradable CyclinD1
(T286A) in RPE-1-hTERT cells,
described in
material and methods
Cell line
(homo sapiens)
female
CyclinD1-Bcl2 RPE-1s This paper N/A Overexpression of
non-degradable CyclinD1
(T286A) and Bcl2 in
RPE-1-hTERT cells,
described in material
and methods
Cell line
(homo sapiens)
female
CyclinD1-Bcl2-p53KO
RPE-1s
This paper N/A Knockout of TP53 and
overexpression of
non-degradable CyclinD1
(T286A) and Bcl2 in
RPE-1-hTERT
cells, described in
material and methods
Antibody Brdu
(recognizing CldU)
Bioconnect Cat# OBT0030G
Clone BU1/75
RRID: AB_609567 (1/500)
Antibody BrdU
(recognizing IdU)
Becton Dickinson Cat# 347580 Clone B44 RRID: AB_10015219 (1/750)
Antibody mouse p53 Abnova Corporation Cat# MAB9657 Clone IMX25 RRID: AB_10756365
(1/1000)
Antibody mouse/
human p21
Santa Cruz Cat# sc-397 C19 RRID: AB_632126 (1/500)
Antibody p27 BD Transduction Laboratory Cat# 554069 RRID: AB_395225 (1/2000)
Antibody CDK4 Santa Cruz Cat# sc-260 C22 RRID: AB_631219 (1/2000)
Antibody Actin Santa Cruz Cat# sc-1616 RRID:AB_630836 (1/1000)
Antibody pChk1 Ser 317 Bethyl Cat# A304-673A RRID: AB_2620868 (1/1000)
Antibody Chk1 Santa Cruz Cat# sc-8408 G4 RRID: AB_627257 (1/1000)
Antibody Rb1 Santa Cruz Cat# sc-50 C15 RRID: AB_632339
(1/500)
Antibody Rbl1 Santa Cruz Cat# sc-318 C18 RRID: AB_2175428 (1/1000)
Antibody Rbl2 Lab Vision Cat# OP117 Clone AB1 RRID: AB_145257
(1/1000)
Antibody Cyclin D1 Santa Cruz Cat# sc-753 H296 RRID: AB_2070433 (1/1000)
Antibody human p53 BD Bioscience Cat# 554293
Clone DO-1
RRID: AB_395348 (1/500)
Antibody Bcl2 Santa Cruz Cat# sc-509 RRID: AB_626733 (1/1000)
Chemical
compound,
drug
2’-deoxyadenosine
monohydrate (dA)
Jena Bioscience N-DN-1001
Chemical
compound,
drug
2’-deoxycytidine
monohydrochloride
(dC)
Jena Bioscience N-DN-6352
Chemical
compound,
drug
2’-deoxyguanosine
monohydrate (dG)
Jena Bioscience N-DN-1003
Chemical
compound,
drug
2’-deoxythymidine
(dT)
Jena Bioscience N-DN-6354
Continued on next page
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Continued
Reagent type
(species) or
resource Designation
Source or
reference Identifiers Additional information
Chemical
compound,
drug
Cell Player 96-well
kinetic
caspase-3/7 reagent
Essen Bioscience Cat# 4440
Chemical
compound,
drug
CldU Sigma Cat# C6891-100mg
Chemical
compound,
drug
IdU Sigma Cat# I7125-5g
Chemical
compound,
drug
BrdU Sigma Cat# B5002-1G
Chemical
compound,
drug
Hydroxyurea (HU) Sigma Cat# H8627
Chemical
compound,
drug
Propidium
Iodide (PI)
Thermo fisher
scientific
Cat# P3566
Chemical
compound,
drug
Puromycin Sigma Cat# P7255
Chemical
compound,
drug
Penincillin/
Streptomycin
Gibco/Life technologies Cat# 15140122
Chemical
compound,
drug
Lipofectamine
2000
Invitrogen Cat# 11668030
Chemical
compound,
drug
Polybrene Sigma Cat# H9268
Chemical
compound,
drug
Fluor-gel
with TES
buffer
Electron Microscopy Science Cat# 17985–30
Software,
algorithm
GraphPad
Prism 7
GraphPad
Software
https://www.graphpad.com/
scientific-software/prism/
Software,
algorithm
Adobe
Photoshop CS6
Adobe https://www.adobe.com/
products/photoshop.html
Software,
algorithm
Adobe
Illustrator CS6
Adobe https://www.adobe.com/
products/illustrator.html
Software,
algorithm
Image
Studio Lite Ver.
4.0
LI-COR Biosciences https://www.licor.com/bio/
products/software/image_
studio_lite/
Software,
algorithm
ImageJ https://imagej.nih.gov/
ij/download.html
Software,
algorithm
FlowJo
software
version 7.6.1
FlowJo, LCC https://www.flowjo.com/
solutions/flowjo/downloads
Software,
algorithm
Casplab Casplab http://casplab.com/download
Cell culture
MEFs were isolated from chimeric embryos as previously described (Dannenberg et al., 2000) and
cultured in GMEM (Invitrogen), supplemented with 10% fetal calf serum (FCS), 0.1 mM nonessential
amino acids (Invitrogen), 1 mM sodium pyruvate (Invitrogen), 100 mg/ml penicillin, 100 mg/ml strep-
tomycin (Invitrogen) and 0.1 mM b-mercaptoeethanol (Merck) in the absence or presence of nucleo-
side (200 nM of Cytidine, Guanosine, Adenosine and Thymidine). TKO-Bcl2 overexpressing MEFs
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and TKO-p53RNAi were generated as described previously (Foijer et al., 2005). CRISPR/Cas9 tech-
nology was used to inactive Trp53 and Cdkn1a.
RPE-1 cells were kindly provided by J. Raaijmakers, who purchased the cells from ATCC. RPE-1
cells were cultured in DMEM/F12+GlutaMAX (Invitrogen), supplemented with 10% FCS, 100 mg/ml
penicillin and 100 mg/ml streptomycin (Invitrogen). CRISPR/Cas9 technology was used to inactivate
Rb, Rbl1, Rbl2 and TP53. Bcl2 cDNA and a non-degradable form of CylcinD1 cDNA was overex-
pressed using retroviral transfection.
For serum starvation experiments, cells were trypsinized and allowed to attach in the presence of
serum for 4 hr. Subsequently, cells were washed with PBS and supplemented with serum free
medium. To block progression into mitosis, cells were cultured in the presence of 250 ng/ml nocoda-
zole. All cell lines have been tested for mycoplasma (PCR).
Constructs, transfections, lentiviral and retroviral infections
The FUCCI constructs CSII-EF-MCS-mKO-hCdt1 (30/120) and CSII-EF-MCS-mAG-hGem (1/110) were
kindly provided by A. Miyawaki (Sakaue-Sawano et al., 2008). The 19-mer Trp53 targeting
sequence in pRetroSuper-RNAi-p53 is GTACATGTGTAATAGCTCC (Foijer et al., 2005). Gene spe-
cific guideRNAs (mouse Trp53: TACCTCTCTTTGCGCTCCCT (Platt et al., 2014); human RB TGAAC-
GACATCTCATCT, human RBL1 TTTCGTGAACGTATAGAA, human RBL2 CGAGGTTGCTCCTC
TTGA and human TP53 GACGCTAGGATCTGACTG) were annealed to generate short double-strand
DNA fragments with four base pairs overhang (CACC and AAAC) compatible with ligation into the
BbsI digested Cas9/CRISPR px330-puro plasmid. The px330-p53 guideRNA vector was transfected
into MEFs using Polyethylenimine (PEI) transfections. The px330-Rb-, px330-Rbl1-, px330-
Rbl2 and px330-p53 guideRNA vectors were transfected into RPE-1 cells using Lipofectamine 2000
(Invitrogen). Afterwards, RPE-1 cells were selected with 10 ug/ml puromycin for two days. Two spe-
cific guideRNAs targeting the mouse Cdkn1a gene were AGCGCAGATTGGTCTTCT and
CCCGCAGCCGTGACGACC with four base pairs overhang (CACC and AAAC) compatible with liga-
tion into the in BmsbI digested pLentiCRISPR v2 vector. The 21-mer oligos in pLKO.1 targeting Ppat
were: #1: CCACATGCTTATGTATGTATA and #2: CCGGAGAAATTGTAGAAATAT. Corresponding
empty vector (EV) was used as control. Lentiviral plasmids were co-transfected with the helper plas-
mids pMDLgpRRE, VSV-G and pRSV-Rec into HEK293T cells by PEI transfection. A pBABE-puro ret-
roviral vector encoding a non-degradable form of Cyclin D1 (T286A) was kindly provided by R.
Agami (Agami and Bernards, 2000). This retroviral vector was co-transfected with the helper plas-
mids puMCV-Gag pol MMLV and pCMV VSVG into HEK293T cells by PEI transfection. Both for lenti-
viral and retroviral transfections, forty-eight and sixty-two hours post transfection viral supernatants
were filtered through 0.45 mm filter and used to infect MEFs in the presence of 4 mg/ml polybrene
three times for 8–12 hr.
Growth curves and caspase assay
The IncuCyte ZOOM instrument (Essen Bioscience) live cell imaging system was used to monitor cell
growth. Cells were plated in a 96 Greiner micro clear plate and imaged every 4 hr. The default soft-
ware parameters for a 96 well plate with a 10x objective were used for imaging. The IncuCyte soft-
ware was used to calculate mean confluence from two non-overlapping bright phase images of each
well.
The IncuCyte ZOOM instrument in combination with the Cell Player 96-well kinetic caspase-3/7
reagent (Essen Bioscience) were used to identify apoptosis by caspase 3/7 activity. The software was
used to calculate mean green fluorescence from two non-overlapping fluorescent images of each
well. Green fluorescent confluency was normalized to phase contrast confluency to determine
apoptosis.
Western blot analysis
Cells were harvested and subsequently lysed for 30 min in RIPA (25 mM Tris-HCl pH 7.6; 150 mM
NaCl; 1% NP-40; 1% Sodiumdeoxycholate and 0.1% SDS) or ELB (150 mM NaCl; 50 mM Hepes
pH7.5; 5 mM EDTA; 0.1% NP-40) containing protease inhibitors (Complete, Roche). Protein concen-
trations were measured using the BCA protein assay kit (Pierce).
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The primary antibodies used were rabbit polyclonal phospho-Chk1 Ser317 (Bethyl), mouse mono-
clonal Chk1 (G4; Santa Cruz), goat polyclonal CDK4 (C22; Santa Cruz), rabbit polyclonal p21 (C19;
Santa Cruz), mouse monoclonal p27 (BD Transduction Laboratory), goat polyclonal Rb (C15; Santa
Cruz); rabbit polyclonal Rbl1 (C18; Santa Cruz), mouse monoclonal Rbl2 (CAS14; Lab Vision), mouse
monoclonal p53 (IMX25; monosan; for detection of mouse p53), mouse monoclonal p53 (DO-1; BD
Biosciences; for detection of human p53), g-tubulin (GTU-88; Sigma), rabbit polyclonal Cyclin D1
(Santa Cruz; H296) and goat polyclonal CDK4 (C22; Santa Cruz). Secondary antibodies used were IR
Dye 800CW Goat anti-Mouse IgG, Goat anti-Rabbit IgG and Donkey anti-Goat IgG (Licor) and HRP-
conjugated Goat anti-Mouse and Goat anti-Rabbit (Dako).
Immunofluorescence
For Rad51 and g-H2AX immunofluorescence staining, cells were cultured on cover slides, washed
with PBS and fixed for 5 min using 4% paraformaldehyde (Merck). Cells were permeabilized by 0.1%
Triton-X100 (sigma) in PBS for 5 min. Subsequently, cells were washed three times using staining
buffer (0.15% glycine (Merck), 0.5% Bovine Serum Albumine (BSA, Sigma) in PBS) and incubated for
1 hr at room temperature in staining buffer. Cells were incubated for 4 hr and 1 hr with primary and
secondary antibodies, respectively.
For CldU and g-H2AX immunofluorescence, cells were cultured on cover slides, incubated with
CldU (100 mM) for 30 min, washed with PBS and fixed for 10 min using 70% EtOH. Cells were
treated with MeOH for 5 min and incubated with 1.5 M HCl for 20 min. Subsequently, cells were
blocked using PBS, 0.5% Tween, 0.25% BSA, 5% FCS for 30 min. Cells were incubated with primary
and secondary antibodies for 2 hr and 1 hr, respectively in PBS, 0.5% Tween,0.25 BSA. Bleaching
was prevented by Vectashield (Vetcor laboratories). The primary antibodies used were rat-anti-BrdU
(Clone BU1/75, Novus Biologicals), rabbit polyclonal Rad51 (a gift from Prof. Roland Kanaar) and
mouse monoclonal phosphorylated H2AX (Upstate) in 1:20, 1:2500 and 1:100 dilutions, respectively.
Secondary antibodies used were Alexa 488-labeled Chicken-anti-Mouse, Alexa 568-labeled Goat-
anti-Rabbit and Alexa 568-labeled Goat-anti-Rat antibodies (Molecular probes) and these were used
in a 1:100 dilution. DNA was stained using To-Pro3 dye (Molecular probes).
DNA fiber analysis
Cells were pulse-labelled with 25 mM CldU followed by 250 mM IdU for 20–40 min each. After label-
ling, cells were trypsinized and lysed in spreading buffer (200 mM Tris-Hcl pH 7.4, 50 mM EDTA and
0.5% SDS) before spreading on a microscope slide (Menzel-Gla¨ser,Superfrost). Slides were fixed in
methanol: acidic acid 3:1. Before immunodetection, slides were treated with 2.5 M HCl for 1 hr and
15 min. To detect CldU and IdU labelled tracts slide were incubated for 1 hr with rat-anti-Brdu
(Clone BU1/75, Novus Biologicals; 1:500) and mouse-anti-BrdU (clone B44, Becton Diskinson; 1:750),
respectively. Subsequently, slides were fixed with 4% paraformaldehyde for 10 min and incubated
with Alexa 488-labeled goat-anti-mouse and Alexa 555-labeled goat-ant-rat (Molecular probes;
1:500) for 1 hr and 30 min. Pictures were taken with a Zeiss AxioObserver Z1 inverted microscope
using a 63x lens equipped with a cooled Hamamatsu ORCA AG Black and White CCD camera and
track lengths were analyzed with ImageJ software. Replication track lengths were calculated using
the conversion factor 1 mm = 2.59 kb (Jackson and Pombo, 1998). The 1-way ANOVA (nonparamet-
ric Kruskal-Wallis test) was used for statistical analyses.
Time-lapse microscopy
Culture dishes were transferred to a heated stage (37˚C) on a Zeiss Axiovert 200M inverted micro-
scope. PhC (phase contrast) images (59 ms exposure) and fluorescent images (red: 500 ms and
green 300 ms exposure) were captured with a 20x/0.25 Ph1 Achroplan objective in combination with
1.6 optovar every 30 min using a cooled Hamamatsu ORCA R2 Black and White CCD-camera and
appropriate filter blocks to select specific fluorescence. Images were taken in 2  2 binning mode
(672  512 pixels) and processed using AxioVision Rel. 4.7.2. software.
Flow cytometry
MEFs cultured in the presence or absence of 10% FCS were labeled with BrdU (10 mM) for 1 hr, fixed
in 70% EtOH and stained with Propidium Iodide (PI). Data acquisition was performed on a Beckman
Benedict et al. eLife 2018;7:e37868. DOI: https://doi.org/10.7554/eLife.37868 20 of 25
Research article Cancer Biology
Coulter Cyan ADP and data analysis (cell cycle) was performed using FlowJo software version 7.6.1
(Tree Star, Ashland, OR, USA).
Comet assay
Neutral comet assays were performed as described by Olive et al. (Olive and Bana´th, 2006). Pic-
tures of individual cells were taken with a Zeiss AxioObserver Z1 inverted microscope equipped with
a cooled Hamamatsu ORCA AG Black and White CCD camera and analyzed with CASP software
(http://www.casp.of.pl). The p-value was determined using 1-way ANOVA (nonparametric Kruskal-
Wallis test).
Generation of chimeric mice and teratomas
All experiments involving animals comply with local and international regulations and ethical guide-
lines (protocol 12026) and have been authorized by our local experimental animal committee at the
Netherlands Cancer Institute (DEC-NKI). Rb-/-Rbl2-/- ESCs were generated previously
(Dannenberg et al., 2004). These cells were injected into C57Bl/6 blastocysts (6 cells per blastocyst)
to generate chimeric mice, which were monitored weekly for retinoblastoma development.
Rb-/-Rbl2-/-p53-/- ESCs were generated using CRISPR/Cas9 technology. One million cells of both cell
lines were injected into the flank of Balb/c nude mice and tumors were harvested 20 days later.
Histological and immunological analysis
Eyes and teratomas were removed immediately after euthanasia and fixed in 4% formaldehyde for
at least 24 hr. For histological analysis, formaldehyde fixed tissues were embedded in paraffin, cut
into 5 mm sections and stained with Hematoxilin and Eosin. The antibodies used were a-p53 (Vector-
Labs), a-p-ATM (Cell signaling), a g H2AX (Cell signaling), a-p-CHK2 (Cell signaling) and a-p-ATM
(Genetex).
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